NDAORALTABLETPriority Review
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
Chloride Channel Activation Potentiators
Pharmacologic Class:
Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
Clinical Trials (1)
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
Started Sep 2009
140 enrolled
Cystic Fibrosis
Loss of Exclusivity
LOE Date
Jan 10, 2043
205 months away
Patent Expiry
Jan 10, 2043
Exclusivity Expiry
Dec 20, 2029